Standout Papers
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (2009)
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) (2011)
Immediate Impact
13 from Science/Nature 206 standout
Citing Papers
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2022 Standout
Atropisomerism in the Pharmaceutically Relevant Realm
2022 Standout
Works of Haiyi Jiang being referenced
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer
2008
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Haiyi Jiang | 6737 | 8090 | 2342 | 52 | 9.7k | |
| Claire Watkins | 7390 | 7692 | 2865 | 41 | 10.8k | |
| Patrapim Sunpaweravong | 5638 | 6959 | 2141 | 56 | 8.3k | |
| David M. Jackman | 4838 | 5496 | 2003 | 87 | 7.4k | |
| Takayuki Kosaka | 5575 | 6417 | 3775 | 92 | 9.2k | |
| Alison Armour | 7273 | 9370 | 2514 | 37 | 11.2k | |
| Caicun Zhou | 6319 | 6649 | 2518 | 135 | 8.7k | |
| Robert T. Heelan | 5459 | 7065 | 2490 | 78 | 9.6k | |
| Chun‐Ming Tsai | 5227 | 6266 | 2013 | 112 | 7.6k | |
| Joo-Hang Kim | 8190 | 6612 | 3050 | 145 | 11.4k | |
| B. Findlay | 6924 | 4771 | 1696 | 44 | 9.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...